US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tvardi Therapeutics Inc

1.78

-0.0800-4.30%

Post-market: 1.780.00000.00%16:10 EDT

Volume:63.24K

Turnover:113.52K

Market Cap:23.74M

PE:-0.64

High:1.87

Open:1.87

Low:1.77

Close:1.86

52wk High:43.65

52wk Low:1.50

Shares:13.34M

Float Shares:5.67M

Volume Ratio:0.39

T/O Rate:1.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.7737

EPS(LYR):-3.2600

ROE:-126.19%

ROA:-55.51%

PB:2.83

PE(LYR):-0.55

Loading ...

Overview Company News Filings

Top Midday Gainers

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Tvardi Therapeutics (TVRD)

Tvardi Says TTI-109 Study Confirms Rapid Prodrug Conversion

MT Newswires Live

Tvardi Therapeutics announces positive Phase 1 results for TTI-109

Tvardi Rises as Oral Inflammation Drug Shows Early-stage Trial Promise

Tvardi Therapeutics Reports Phase 1 Data for STAT3 Inhibitor Prodrug Tti-109 Showing Improved Tolerability

Tvardi Therapeutics’ Tti-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of Stat3 Target Engagement

THOMSON REUTERS

Tvardi Therapeutics - Tti-109 Shows Rapid Conversion and up to 60% Reduction in Stat3-driven Immune Cells

THOMSON REUTERS

Tvardi Therapeutics : Plans to Advance Tti-109 into Stat3-driven Dermatologic & Gastrointestinal Diseases - Subject to Additional Funding

THOMSON REUTERS

H.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)

Tvardi Therapeutics shareholders elected directors at annual meeting

Tvardi Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $9

THOMSON REUTERS

Tvardi Therapeutics to Participate in Upcoming Investor Events

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Tvardi Therapeutics (TVRD) and Organigram Global (OGI)

Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)

Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD)

Tvardi Therapeutics (TVRD) Receives a Buy from BTIG

Tvardi Therapeutics Q1 net loss narrows

Tvardi Therapeutics Inc - Tti-109 Topline Data and Clinical Strategy Announcement Expected in June 2026

THOMSON REUTERS

Tvardi Therapeutics Inc - Topline Data From Phase 2 Trial of Tti-101 in Hepatocellular Carcinoma (Hcc) on Track for 2H 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/TVRD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":1.78,"timestamp":1787601600000,"preClose":1.86,"halted":0,"volume":63238,"hourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.78,"latestTime":"16:10 EDT","volume":116,"amount":206.48,"timestamp":1787602205422,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04301075268817208,"floatShares":5671300,"shares":13338900,"eps":-2.773725,"marketStatus":"Post-Mkt","change":-0.08,"latestTime":"08-24 17:25:55 EDT","open":1.87,"high":1.87,"low":1.77,"amount":113524,"amplitude":0.053763,"askPrice":1.98,"askSize":100,"bidPrice":1.75,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-2.773725,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":1.86,"preHourTrading":{"tag":"盘前","latestPrice":1.86,"preClose":1.86,"latestTime":"08:10 EDT","volume":8,"amount":14.88,"timestamp":1787573450023,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.78,"preClose":1.78,"latestTime":"16:10 EDT","volume":116,"amount":206.48,"timestamp":1787602205422,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.390703,"impliedVol":1.5577,"impliedVolPercentile":0.4667},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":5671300,"roa":"-55.51%","roe":"-126.19%","lyrEps":-3.259999,"volumeRatio":0.390703,"shares":13338900,"dividePrice":0,"high":1.87,"amplitude":0.053763,"preClose":1.86,"low":1.77,"week52Low":1.5,"pbRate":"2.83","week52High":43.65,"institutionHeld":0,"latestPrice":1.78,"committee":0.818182,"eps":-2.773725,"divideRate":0,"volume":63238,"delay":0,"ttmEps":-2.773725,"open":1.87,"prevYearClose":4.3,"prevWeekClose":1.86,"prevMonthClose":2.1,"prevQuarterClose":1.9,"fiveDayClose":1.86,"twentyDayClose":2.54,"sixtyDayClose":3.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"TVRD","fiscalQuarterEnding":"2026/06","expectedEps":-0.65,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2026-05-08","symbol":"TVRD","fiscalQuarterEnding":"2026/03","expectedEps":-0.65,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":-0.73},{"market":"US","date":"2026-03-31","symbol":"TVRD","fiscalQuarterEnding":"2025/12","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2025-11-13","symbol":"TVRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2025-08-14","symbol":"TVRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.5556,"hold":0.1111,"sell":0.1111,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1783569600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVRD","date":"2026-08-21","current":-0.645342,"percent":1,"low":-17.054928,"twenty":-6.271824,"median":-1.674248,"eighty":-1.509204,"high":-0.658706,"avg":-3.691539,"sd":4.310319,"marketCap":17167859},"quantilePoints":[{"date":"2025-08-01","current":-6.984237,"twenty":-7.018674,"median":-6.984237,"eighty":-6.867475,"marketCap":242869870},{"date":"2025-08-08","current":-6.220168,"twenty":-7.05634,"median":-6.986928,"eighty":-6.651705,"marketCap":216300131},{"date":"2025-08-15","current":-6.400424,"twenty":-7.003609,"median":-6.690985,"eighty":-6.397734,"marketCap":222568344},{"date":"2025-08-22","current":-10.573024,"twenty":-9.576632,"median":-6.986928,"eighty":-6.42948,"marketCap":249861702},{"date":"2025-08-29","current":-12.013447,"twenty":-10.759129,"median":-7.048807,"eighty":-6.480866,"marketCap":283901784},{"date":"2025-09-05","current":-12.078921,"twenty":-11.588463,"median":-7.134899,"eighty":-6.493511,"marketCap":285449060},{"date":"2025-09-12","current":-14.047103,"twenty":-11.928926,"median":-9.803211,"eighty":-6.612426,"marketCap":331961128},{"date":"2025-09-19","current":-15.372451,"twenty":-12.457478,"median":-10.666275,"eighty":-6.823352,"marketCap":363281754},{"date":"2025-09-26","current":-14.606606,"twenty":-13.432046,"median":-11.499578,"eighty":-6.955181,"marketCap":345183308},{"date":"2025-10-03","current":-14.82882,"twenty":-14.620891,"median":-11.737664,"eighty":-6.987466,"marketCap":350434671},{"date":"2025-10-10","current":-17.054928,"twenty":-14.850248,"median":-11.943013,"eighty":-6.991233,"marketCap":403042070},{"date":"2025-10-17","current":-2.571334,"twenty":-14.850248,"median":-11.769409,"eighty":-6.823352,"marketCap":60765765},{"date":"2025-10-24","current":-2.047544,"twenty":-14.833582,"median":-11.58886,"eighty":-6.422216,"marketCap":48387554},{"date":"2025-10-31","current":-1.849138,"twenty":-14.74787,"median":-11.130543,"eighty":-4.843171,"marketCap":43698837},{"date":"2025-11-07","current":-1.563435,"twenty":-14.662953,"median":-10.195062,"eighty":-2.595143,"marketCap":36947086},{"date":"2025-11-14","current":-1.631573,"twenty":-14.620891,"median":-9.523459,"eighty":-2.06421,"marketCap":38557323},{"date":"2025-11-21","current":-1.515552,"twenty":-14.489944,"median":-7.06764,"eighty":-1.887232,"marketCap":35836734},{"date":"2025-11-28","current":-1.634574,"twenty":-14.266143,"median":-6.990963,"eighty":-1.811838,"marketCap":38651137},{"date":"2025-12-05","current":-1.658378,"twenty":-13.805842,"median":-6.911597,"eighty":-1.667399,"marketCap":39214017},{"date":"2025-12-12","current":-1.781368,"twenty":-13.436014,"median":-6.493242,"eighty":-1.662637,"marketCap":42122234},{"date":"2025-12-19","current":-1.543324,"twenty":-13.412999,"median":-6.400424,"eighty":-1.660082,"marketCap":36493428},{"date":"2025-12-26","current":-1.5949,"twenty":-13.32332,"median":-6.349307,"eighty":-1.639335,"marketCap":37713002},{"date":"2026-01-02","current":-1.705987,"twenty":-13.031267,"median":-2.777676,"eighty":-1.642509,"marketCap":40339779},{"date":"2026-01-09","current":-1.678216,"twenty":-12.62652,"median":-2.62292,"eighty":-1.634574,"marketCap":39683085},{"date":"2026-01-16","current":-1.789303,"twenty":-12.344784,"median":-2.448323,"eighty":-1.634574,"marketCap":42309861},{"date":"2026-01-23","current":-1.91626,"twenty":-12.181298,"median":-2.07532,"eighty":-1.634574,"marketCap":45311891},{"date":"2026-01-30","current":-1.547291,"twenty":-12.091222,"median":-1.95231,"eighty":-1.634574,"marketCap":36587241},{"date":"2026-02-06","current":-1.408431,"twenty":-12.026542,"median":-1.896756,"eighty":-1.617117,"marketCap":33303771},{"date":"2026-02-13","current":-1.475877,"twenty":-11.900753,"median":-1.8627,"eighty":-1.598129,"marketCap":34898599},{"date":"2026-02-20","current":-1.424301,"twenty":-11.810677,"median":-1.847154,"eighty":-1.590139,"marketCap":33679024},{"date":"2026-02-27","current":-1.606802,"twenty":-11.750362,"median":-1.836912,"eighty":-1.577443,"marketCap":37994443},{"date":"2026-03-06","current":-1.5949,"twenty":-11.649572,"median":-1.807157,"eighty":-1.573476,"marketCap":37713002},{"date":"2026-03-13","current":-1.458024,"twenty":-11.588463,"median":-1.789617,"eighty":-1.565651,"marketCap":34476439},{"date":"2026-03-20","current":-1.460008,"twenty":-11.482118,"median":-1.781368,"eighty":-1.559193,"marketCap":34523345},{"date":"2026-03-27","current":-1.321148,"twenty":-11.243237,"median":-1.741999,"eighty":-1.553639,"marketCap":31239875},{"date":"2026-04-02","current":-1.545187,"twenty":-10.944836,"median":-1.71789,"eighty":-1.546029,"marketCap":28144032},{"date":"2026-04-10","current":-1.524584,"twenty":-10.628975,"median":-1.704004,"eighty":-1.543324,"marketCap":27768778},{"date":"2026-04-17","current":-1.6585,"twenty":-10.270654,"median":-1.682478,"eighty":-1.543324,"marketCap":30207927},{"date":"2026-04-24","current":-1.550337,"twenty":-9.805989,"median":-1.678216,"eighty":-1.544069,"marketCap":28237845},{"date":"2026-05-01","current":-1.622446,"twenty":-9.682977,"median":-1.674248,"eighty":-1.546029,"marketCap":29551233},{"date":"2026-05-08","current":-2.168412,"twenty":-8.568035,"median":-1.676379,"eighty":-1.548509,"marketCap":39495458},{"date":"2026-05-15","current":-2.406252,"twenty":-7.115528,"median":-1.682478,"eighty":-1.550705,"marketCap":37150122},{"date":"2026-05-22","current":-2.181425,"twenty":-7.071406,"median":-1.707971,"eighty":-1.552845,"marketCap":33679024},{"date":"2026-05-29","current":-2.120661,"twenty":-7.037507,"median":-1.719873,"eighty":-1.555226,"marketCap":32740890},{"date":"2026-06-05","current":-1.871529,"twenty":-6.991771,"median":-1.746061,"eighty":-1.555226,"marketCap":28894539},{"date":"2026-06-12","current":-1.646703,"twenty":-6.988542,"median":-1.736886,"eighty":-1.555278,"marketCap":25423442},{"date":"2026-06-18","current":-1.56771,"twenty":-6.984237,"median":-1.719873,"eighty":-1.555488,"marketCap":24203867},{"date":"2026-06-26","current":-1.434029,"twenty":-6.911597,"median":-1.705987,"eighty":-1.555226,"marketCap":22139971},{"date":"2026-07-02","current":-1.184897,"twenty":-6.735107,"median":-1.689237,"eighty":-1.549728,"marketCap":18293620},{"date":"2026-07-10","current":-2.30903,"twenty":-6.533867,"median":-1.695629,"eighty":-1.54687,"marketCap":35649107},{"date":"2026-07-17","current":-1.871529,"twenty":-6.492435,"median":-1.709955,"eighty":-1.549728,"marketCap":28894539},{"date":"2026-07-24","current":-1.555557,"twenty":-6.447775,"median":-1.713922,"eighty":-1.551074,"marketCap":24016240},{"date":"2026-07-31","current":-1.276043,"twenty":-6.414952,"median":-1.704004,"eighty":-1.544474,"marketCap":19700822},{"date":"2026-08-07","current":-1.124133,"twenty":-6.392353,"median":-1.682478,"eighty":-1.541737,"marketCap":17355486},{"date":"2026-08-14","current":-1.075522,"twenty":-6.364373,"median":-1.67765,"eighty":-1.526306,"marketCap":16604978},{"date":"2026-08-21","current":-0.658706,"twenty":-6.271824,"median":-1.674248,"eighty":-1.509204,"marketCap":17167859}],"updateTime":1787593745819},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649338934","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2649338934","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649338934?lang=en_us&edition=fundamental","pubTime":"2026-07-08 01:36","pubTimestamp":1783445779,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  and Crinetics Pharmaceuticals  said late Monday they have reached an agreement for Vertex to buy Crinetics for $85 per share in cash. The deal has a total equity value of about $10 billion and is expected to close in Q3, the companies said.Shares of Crinetics almost doubled amid a surge in intraday trading volume to over 67.1 million from a daily average of roughly 1.30 million.MeiraGTx  has signed a deal under which Oberland Capital Management has agreed to invest up to $400 million in the company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity, it said Tuesday.Shares jumped 8.2% following an increase in intraday trading volume to over 1.01 million from a daily average of about 987,000.Tvardi Therapeutics  said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1069344957.HKD","IBBQ","SG9999001176.SGD","IE00B19Z9Z06.USD","LU1035775433.USD","IE00B19Z3B42.SGD","PBE","LU0289739699.SGD","LU2456880835.USD","LU0889565916.HKD","IE00B894F039.SGD","LU0432979614.USD","LU2362541273.HKD","TVRD","BK4007","LU2324357040.USD","LU0320765992.SGD","BK4532","CRNX","IE0009355771.USD","IE00BJJMRZ35.SGD","LU1430594728.SGD","VRTX","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4588","LU2236285917.USD","LU0058720904.USD","BIB","LU1093756325.SGD","IE0002270589.USD","LU0079474960.USD","BK4533","LU0417517546.SGD","SG9999001176.USD","LU0109394709.USD","LU0234570918.USD","LU1674673428.USD","LU0823416689.USD","BK4567","LU0256863811.USD","IE00B2B36J28.USD","BBH","LU1585245621.USD","IBB","IE00BZ9MQY76.HKD","IDNA","MGTX","IE00BJT1NW94.SGD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649931530","title":"Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649931530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649931530?lang=en_us&edition=fundamental","pubTime":"2026-07-08 00:10","pubTimestamp":1783440610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS) and Tvardi Therapeutics (TVR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-pathways-cmps-and-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-pathways-cmps-and-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS","XLV","LU0029874061.USD","HCSG","LU0128526141.USD","BK4139","PSIL","BK4581","BK4585","BK4137","XBI","TVRD","BK4588","LABU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649935551","title":"Tvardi Says TTI-109 Study Confirms Rapid Prodrug Conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=2649935551","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649935551?lang=en_us&edition=fundamental","pubTime":"2026-07-07 22:21","pubTimestamp":1783434097,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics  said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101,  producing nearly identical plasma levels at molar-equivalent doses, and validating its prodrug design.Other key findings include sustained target-level exposure, evidence of target engagement, and improved tolerability against TTI-101, the company said.Tvardi said it plans to advance TTI-109 across dermatologic and gastrointestinal diseases, subject to additional funding.Shares were up almost 30% in morning trading.Price: 2.60, Change: +0.59, Percent Change: +29.35","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4179","IE00B19Z4B17.USD","IE0031619046.USD","IE00B66KJ199.SGD","BK4007","TVRD","IE00B7SZL793.SGD","TTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649938615","title":"Tvardi Therapeutics announces positive Phase 1 results for TTI-109","url":"https://stock-news.laohu8.com/highlight/detail?id=2649938615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649938615?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:10","pubTimestamp":1783429823,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics (TVRD) announced results from its Phase 1 study of TTI-109, its next-generation STAT3 inhibitor. The study confirmed that TTI-1...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-announces-positive-phase-1-results-for-tti-109-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tvardi-therapeutics-announces-positive-phase-1-results-for-tti-109-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD","IE00B66KJ199.SGD","IE00B19Z4B17.USD","LENZ","TTI","IE0031619046.USD","BK4139","BK4007","BK4179","BK4539","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982647","title":"Tvardi Rises as Oral Inflammation Drug Shows Early-stage Trial Promise","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982647","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649982647?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:48","pubTimestamp":1783424911,"startTime":"0","endTime":"0","summary":"BUZZ-Tvardi rises as oral inflammation drug shows early-stage trial promise** Shares of drug developer Tvardi TherapeuticsTVRD.Orise 2% to $2.03 premarket** Co says its oral experimental drug TTI-109 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N4390Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649798487","title":"Tvardi Therapeutics Reports Phase 1 Data for STAT3 Inhibitor Prodrug Tti-109 Showing Improved Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2649798487","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649798487?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:01","pubTimestamp":1783422085,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics reports Phase 1 data for STAT3 inhibitor prodrug TTI-109 showing improved tolerabilityTvardi Therapeutics reported Phase 1 results for STAT3 inhibitor prodrug TTI-109, citing impro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDLmjdHj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00B64PRP62.GBP","TVRD","IE00BGHQF748.EUR","BK4588","IE00BN0W2T93.GBP","LU2095319765.USD","BK4112","NDAQ","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4007","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014021.USD","BCDF","LU0314104364.USD","SG9999014039.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649981767","title":"Tvardi Therapeutics’ Tti-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of Stat3 Target Engagement","url":"https://stock-news.laohu8.com/highlight/detail?id=2649981767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649981767?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA99GQF9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649817669","title":"Tvardi Therapeutics - Tti-109 Shows Rapid Conversion and up to 60% Reduction in Stat3-driven Immune Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2649817669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649817669?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA99GQF9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649798127","title":"Tvardi Therapeutics : Plans to Advance Tti-109 into Stat3-driven Dermatologic & Gastrointestinal Diseases - Subject to Additional Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2649798127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649798127?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA99GQF9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646810690","title":"H.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646810690","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646810690?lang=en_us&edition=fundamental","pubTime":"2026-06-25 01:55","pubTimestamp":1782323723,"startTime":"0","endTime":"0","summary":"In a report released today, Sara Nik from H.C. Wainwright initiated coverage with a Buy rating on Tvardi Therapeutics and a price target of $9.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-initiates-a-buy-rating-on-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-initiates-a-buy-rating-on-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642311762","title":"Tvardi Therapeutics shareholders elected directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642311762","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642311762?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:07","pubTimestamp":1781208423,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics held its annual shareholder meeting on June 9, 2026.Shareholders backed the board’s director slate for Class II seats, setting terms running to the 2029 annual meeting.Investors endorsed an annual cadence for future advisory votes on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLc05KKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641483041","title":"Tvardi Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2641483041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641483041?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:20","pubTimestamp":1780914043,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nAZN4T15LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637337003","title":"Tvardi Therapeutics to Participate in Upcoming Investor Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2637337003","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637337003?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364800,"startTime":"0","endTime":"0","summary":"HOUSTON, May  21, 2026  (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299274/0/en/Tvardi-Therapeutics-to-Participate-in-Upcoming-Investor-Events.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","TVRD","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223212","title":"Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Tvardi Therapeutics (TVRD) and Organigram Global (OGI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223212","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223212?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:10","pubTimestamp":1778620207,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Legend Biotech (LEGN), Tvardi Therapeutics (TVRD) and Organigram ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-legend-biotech-legn-tvardi-therapeutics-tvrd-and-organigram-global-ogi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-legend-biotech-legn-tvardi-therapeutics-tvrd-and-organigram-global-ogi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","TVRD","LU0029874061.USD","XLV","BK4581","LU0128526141.USD","OGI","BK4585","LABU","LEGN","BK4557","BK4137","BK4588","HCSG","BK4007","XBI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634899742","title":"Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634899742","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634899742?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:20","pubTimestamp":1778502049,"startTime":"0","endTime":"0","summary":"In a report released today, from Oppenheimer maintained a Buy rating on Tvardi Therapeutics, with a price target of $10.00. In addition to Oppenhei...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-its-buy-rating-for-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285424","title":"Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285424","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634285424?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:36","pubTimestamp":1778499363,"startTime":"0","endTime":"0","summary":"In a report released on May 8, from Cantor Fitzgerald maintained a Hold rating on Tvardi Therapeutics. The company’s shares closed last Friday at $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-hold-rating-for-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-hold-rating-for-tvardi-therapeutics-tvrd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634494440","title":"Tvardi Therapeutics (TVRD) Receives a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2634494440","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634494440?lang=en_us&edition=fundamental","pubTime":"2026-05-10 21:45","pubTimestamp":1778420701,"startTime":"0","endTime":"0","summary":"In a report released on May 8, Julian Harrison from BTIG maintained a Buy rating on Tvardi Therapeutics, with a price target of $15.00. The company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tvardi-therapeutics-tvrd-receives-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tvardi-therapeutics-tvrd-receives-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633458308","title":"Tvardi Therapeutics Q1 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2633458308","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633458308?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:11","pubTimestamp":1778238692,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Q1 net loss narrowsOverviewUS biopharma firm's Q1 net loss narrowed yr/yrR&D and G&A expenses rose due to higher development and personnel costsCompany expects cash runway to fund ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL1N41L0EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633588464","title":"Tvardi Therapeutics Inc - Tti-109 Topline Data and Clinical Strategy Announcement Expected in June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633588464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633588464?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA9MM6BK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633458817","title":"Tvardi Therapeutics Inc - Topline Data From Phase 2 Trial of Tti-101 in Hepatocellular Carcinoma (Hcc) on Track for 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633458817","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633458817?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:00","pubTimestamp":1778238002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA9MM6BK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":59,"code":"91000000","status":"200"}]}}